MoonLake Immunotherapeutics (MLTX NASDAQ) stock market data APIs
$18.7111
-1.23(-6.6%)
as of April 8, 2026
Try our APIs with
free plan!
MoonLake Immunotherapeutics Financial Data Overview
Price chart is built with
Anychart
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Prev. Close
18.7111
Open
17.4765
High
18.8873
Low
17.2548
52 wk Range
5.95-62.75
Market Cap
1 334 M
Shares Outstanding
71 728 K
EPS
-0.92
Beta
1.189
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with MoonLake Immunotherapeutics (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MoonLake Immunotherapeutics data using free add-ons & libraries
Get MoonLake Immunotherapeutics Fundamental Data
MoonLake Immunotherapeutics Fundamental data includes:
- Net Revenue:
- EBITDA: -242 218 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: -0.9792
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MoonLake Immunotherapeutics News
New
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
Key Points BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039...
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
On April 2, 2026, MoonLake Immunotherapeutics(NASDAQ:MLTX) BVF Partners L.P. reported the direct sale of 3,750,000 shares of Common Stock for a total consideration of approximately $62.96 million, acc...
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently reported long-term Week 40 results from its Phase 3 VELA-1 and VELA-2 trials in moderate-to-severe hidradenitis suppurativa, showing sustained clinical responses a...
MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says
MoonLake Immunotherapeutics (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Get MoonLake Immunotherapeutics fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
